Claro Advisors LLC Decreases Position in Amgen Inc. $AMGN

Claro Advisors LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 18.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,359 shares of the medical research company’s stock after selling 761 shares during the quarter. Claro Advisors LLC’s holdings in Amgen were worth $938,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Brighton Jones LLC boosted its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Abel Hall LLC acquired a new position in Amgen in the 1st quarter worth $232,000. Envestnet Asset Management Inc. increased its position in shares of Amgen by 12.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,419,605 shares of the medical research company’s stock worth $442,278,000 after purchasing an additional 152,514 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its position in shares of Amgen by 7.8% during the first quarter. U.S. Capital Wealth Advisors LLC now owns 17,771 shares of the medical research company’s stock worth $5,537,000 after purchasing an additional 1,291 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC lifted its position in shares of Amgen by 2.3% during the first quarter. Beverly Hills Private Wealth LLC now owns 1,932 shares of the medical research company’s stock worth $602,000 after purchasing an additional 44 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.76% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $296.70 on Wednesday. The stock has a market cap of $159.73 billion, a P/E ratio of 24.26, a PEG ratio of 2.61 and a beta of 0.49. The company’s 50-day simple moving average is $288.05 and its 200 day simple moving average is $287.76. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period in the prior year, the firm earned $5.58 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio (DPR) is currently 77.84%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Morgan Stanley increased their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. UBS Group decreased their price objective on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 27th. Piper Sandler lifted their target price on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research note on Monday, August 25th. Finally, Raymond James Financial assumed coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating for the company. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $300.94.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.